IL13 and neoplasm: TAMs at the tumor site, stimulated by different cytokines, differentiate into M1-type macrophages (pro-inflammatory phenotype) with anti-tumor effects or M2-type macrophages (anti-inflammatory phenotype) that inhibit anti-tumor effects and release IL-4, IL-10, and IL-13 [115].